ICVTS Click here for other ICVTS advertising opportunities
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Interact CardioVasc Thorac Surg 2006;5:263-267. doi:10.1510/icvts.2005.120352
© 2006 European Association of Cardio-Thoracic Surgery

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dalmau, M. J.
Right arrow Articles by Arribas, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dalmau, M. J.
Right arrow Articles by Arribas, A.
Related Collections
Right arrow Valve disease

Institutional report - Valves

The Carpentier-Edwards Perimount Magna aortic xenograft: a new design with an improved hemodynamic performance{star}

María José Dalmaua,*, José MaríaGonzález-Santosa, Javier López-Rodrígueza, Maria Buenoa and Antonio Arribasb

a Department of Cardiac Surgery, Salamanca University Hospital, Paseo de San Vicente 58-182, 37007 Salamanca, Spain
b Department of Cardiology, Salamanca University Hospital, Paseo de San Vicente 58-182, 37007 Salamanca, Spain

*Corresponding author. Tel.: +34-923291383; fax: +34-923291383.

E-mail address: dalmau_mjo{at}gva.es (M.J. Dalmau).

This study compares the implantation characteristics and the hemodynamic performance of the new Carpentier-Edwards Perimount Magna (CEPM) xenograft with those of the standard Perimount (CEPS) valve in the aortic position. Eighty consecutive patients surviving an aortic valve replacement with either the CEPS valve (n=40) or the CEPM prosthesis (n=40) in the supra-annular position were retrospectively reviewed. One year follow-up was complete and hemodynamic performance assessed by Doppler echocardiography. The mean valve size implanted was 21.3±1.7 mm (CEPS) vs. 22.2±1.8 mm (CEPM). The average mean pressure gradient was 13.6±5.1 mmHg in the CEPS group and 9.6±3.3 mmHg in the CEPM group (P<0.0001). Mean and peak gradients were slightly lower and the effective orifice areas (EOA) were larger for the Magna prosthesis than for the comparable standard valves: 19 mm (1.58±0.2 vs. 1.28±0.1 cm2), 21 mm (1.90±0.4 vs. 1.69±0.4 cm2), 23 mm (2.07±0.3 vs. 1.86±0.3 cm2), 25 mm (2.30±0.1 vs. 1.89±0.5 cm2). The average indexed EOA was statistically different between groups (CEPS 0.98±0.21 cm2/m2 vs. CEPM 1.20±0.25 cm2/m2). Patient-prosthesis mismatch (indexed EOA≤0.85 cm2/m2) was present in 40.7% (CEPS) vs. 16.6% (CEPM) of the patients with valve sizes ≤21 mm. Our study demonstrates that the Magna prosthesis significantly reduces the incidence of patient-prosthesis mismatch when compared to the standard Perimount valve in the aortic position.

Key Words: Aortic valve replacement; Tissue valves; Hemodynamic performance







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 European Association for Cardio-thoracic Surgery